Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  • Dick de Zeeuw
  • Tadao Akizawa
  • Rajiv Agarwal
  • Paul Audhya
  • George L Bakris
  • Melanie Chin
  • Melissa Krauth
  • Hiddo J Lambers Heerspink
  • Colin J Meyer
  • John J McMurray
  • Hans-Henrik Parving
  • Pablo E Pergola
  • Giuseppe Remuzzi
  • Robert D Toto
  • Nosratola D Vaziri
  • Christoph Wanner
  • David G Warnock
  • Janet Wittes
  • Glenn M Chertow
View graph of relations
Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.
Original languageEnglish
JournalAmerican Journal of Nephrology
Volume37
Issue number3
Pages (from-to)212-22
Number of pages11
ISSN0250-8095
DOIs
Publication statusPublished - 2013

ID: 38879053